Epidemiology of respiratory syncytial virus within a New South Wales-based multi-centre health district between 2018 and 2024 in Australia

Respiratory syncytial virus (RSV) epidemiology in Australia is unclear given recent advances in diagnostic testing, COVID-19 interventions, and under-recognition in older adults. Data are needed to inform new RSV vaccine use. We analysed laboratory data from all viral respiratory reverse transcription quantitative polymerase chain reaction (RT-qPCR) diagnostic tests conducted at New South Wales (NSW) Health Pathology in the South Eastern Sydney and Illawarra Health Service from 2018 to 2024. Panel and descriptive analyses were used to report annual RSV testing and detection by age group, care setting, and co-infection with other respiratory viruses using Stata v.18. Of 370,126 unique episodes tested for RSV, there were 13,293 (3.6%) detections. Public health measures for COVID-19 significantly impacted RSV circulation in 2020, with detections nearly absent in the winter season (June-August) and an off-season epidemic occurring in the summer. Annual testing and detection peaked in 2022 and was considerably higher than in pre-pandemic years (testing 6.3-fold and detection 3.4-fold higher than in 2019, respectively). Across the study period, incidence was highest in children aged <5 years (1,613 per 100,000 population). Among older adults (≥60 years of age), prevalence was 125 per 100,000. Testing was primarily performed in outpatients (71%), of which emergency departments were the most frequent care setting (49%). Of all detections, 2,713 (20.4%) had co-infections, with the most commonly co-detected viruses being rhinovirus (37%) and bocavirus (17%). RSV testing increased from 2022 due to expanded respiratory screening, RSV becoming a notifiable disease, and COVID-19 epidemics. Multiplex RT-qPCR testing increased RSV detection, but testing bias exists, with children tested more than adults. Continued surveillance across age groups is essential to assess the impact of new immunisation strategies.

Authors

Institutions

Publication Details

Journal
Pathology
Published
2025-08-29
DOI
https://doi.org/10.1016/j.pathol.2025.06.011
Citations
2
Primary Topic
Respiratory viral infections research
Type
article
Field-Weighted Citation Impact
2.71

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Epidemiology of respiratory syncytial virus within a New South Wales-based multi-centre health district between 2018 and 2024 in Australia

Zubair Akhtar, Gregory J. Walker, William D. Rawlinson, Adriana Notaras et al.
2 citations
Pathology
Respiratory viral infections research
2.71
article

Epidemiology of respiratory syncytial virus within a New South Wales-based multi-centre health district between 2018 and 2024 in Australia

Zubair Akhtar, Gregory J. Walker, William D. Rawlinson, Adriana Notaras, Mohana Kunasekaran, C. Raina MacIntyre, Essa Tawfiq
article en
2 citations

Abstract

Respiratory syncytial virus (RSV) epidemiology in Australia is unclear given recent advances in diagnostic testing, COVID-19 interventions, and under-recognition in older adults. Data are needed to inform new RSV vaccine use. We analysed laboratory data from all viral respiratory reverse transcription quantitative polymerase chain reaction (RT-qPCR) diagnostic tests conducted at New South Wales (NSW) Health Pathology in the South Eastern Sydney and Illawarra Health Service from 2018 to 2024. Panel and descriptive analyses were used to report annual RSV testing and detection by age group, care setting, and co-infection with other respiratory viruses using Stata v.18. Of 370,126 unique episodes tested for RSV, there were 13,293 (3.6%) detections. Public health measures for COVID-19 significantly impacted RSV circulation in 2020, with detections nearly absent in the winter season (June-August) and an off-season epidemic occurring in the summer. Annual testing and detection peaked in 2022 and was considerably higher than in pre-pandemic years (testing 6.3-fold and detection 3.4-fold higher than in 2019, respectively). Across the study period, incidence was highest in children aged <5 years (1,613 per 100,000 population). Among older adults (≥60 years of age), prevalence was 125 per 100,000. Testing was primarily performed in outpatients (71%), of which emergency departments were the most frequent care setting (49%). Of all detections, 2,713 (20.4%) had co-infections, with the most commonly co-detected viruses being rhinovirus (37%) and bocavirus (17%). RSV testing increased from 2022 due to expanded respiratory screening, RSV becoming a notifiable disease, and COVID-19 epidemics. Multiplex RT-qPCR testing increased RSV detection, but testing bias exists, with children tested more than adults. Continued surveillance across age groups is essential to assess the impact of new immunisation strategies.

PathologyVol. 58(1)
New South Wales Department of Health (AU), UNSW Sydney (AU)
GlaxoSmithKline, GlaxoSmithKline Australia
Good health and well-being
Openalex Percentile: Top 9%
Respiratory viral infections research
2.71
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.